Open access · US-GOV
via ClinicalTrials.gov Clinical trial
A Phase III Safety and Efficacy Study of ALZT-OP1 in Subjects With Evidence of Early Alzheimer's Disease
Authors not listed
AZTherapies, Inc. · 2015
Abstract
This is a global Phase III, randomized, double-blinded, placebo-controlled study for subjects with evidence of early AD. The protocol is designed to determine whether ALZT-OP1 combination treatment (ALZT-OP1a + ALZT-OP1b) will slow down, arrests, or reverse cognitive and functional decline, in subjects with evidence of early stage Alzheimer's disease (AD).
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- ClinicalTrials.gov
- Canonical
- link ↗
- Fetched
- 2026-11-13 MST
Cite this
APA
Anonymous. (2015). A Phase III Safety and Efficacy Study of ALZT-OP1 in Subjects With Evidence of Early Alzheimer's Disease. <em>AZTherapies, Inc.</em>. https://clinicaltrials.gov/study/NCT02547818
Vancouver
Anonymous. A Phase III Safety and Efficacy Study of ALZT-OP1 in Subjects With Evidence of Early Alzheimer's Disease. AZTherapies, Inc.. 2015.
BibTeX
@misc{anon2015APhase,
title = {A Phase III Safety and Efficacy Study of ALZT-OP1 in Subjects With Evidence of Early Alzheimer's Disease},
author = {Anonymous},
journal = {AZTherapies, Inc.},
year = {2015},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
Inmune Bio, Inc. 2022
Open access · US-GOV
A Randomized, Placebo-Controlled, Double-Blind Study of XPro1595 in Patients With Early Alzheimer's Disease With Biomarkers of Inflammation
University of Wisconsin, Madison 2019
Open access · US-GOV
Longitudinal Evaluation of [18-F]MK-6240 as a Novel Tau PET Radiotracer in Patients With Alzheimer's Disease Dementia or Mild Cognitive Impairment Compared to Healthy Volunteers
The University of Texas at Dallas 2018
Open access · US-GOV
Strategic Training to Optimize Neurocognitive Functions in Older Adults
IGC Pharma, LLC 2021
Open access · US-GOV
A Phase I Randomized Placebo Controlled MAD Study to Evaluate Safety and Tolerability of IGC-AD1 in Subjects With Dementia Due to Alzheimer's Disease
Neuron 2012
Open access · OA
Propagation of Tau Pathology in a Model of Early Alzheimer's Disease
US Department of Veterans Affairs 1999
Open access · US-GOV